Centre National De La Recherche Scientifique

Universitè De Montpellier

Philippe Fort

Pierre Roux

Gilles Gadea

Nikola Arsic

Véronique Gire

Jean-Paul Leonetti

Mylène Weill

Fanny Thomas

Michel Raymond

Nicole Pasteur

Fanny Tomas

Peggy Raynaud

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression; and also to screening methods for anti-cancer stem cells agents.

Delta133P53Beta and Delta133P53Gamma isoforms are biomarkers of cancer stem cells

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of &#x394;133&#x3c1;536 isoform, &#x394;133&#x3c1;53&#x3b3; isoform, or both &#x394;133&#x3c1;536 and &#x394;133&#x3c1;53&#x3b3; isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in &#x394;133&#x3c1;536 isoform, &#x394;133&#x3c1;53&#x3b3; isoform, or both &#x394;133&#x3c1;536 and &#x394;133&#x3c1;53&#x3b3; isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing &#x394;133p536 isoform, &#x394;133&#x3c1;53&#x3b3; isoform, or both &#x394;133&#x3c1;536 and &#x394;133&#x3c1;53&#x3b3; isoforms expression; and also to screening methods for anti-cancer stem cells agents.

Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells

The invention relates to the use of compounds derived from pyrimidinetrione of general formula (I) as acetyl cholinesterase (AChE) inhibitors. The invention also relates to the use of said compounds as insecticides, and to compositions containing the same.

Use of compounds derived from pyrimidinetrione as acetyl cholinesterase inhibitors, compositions containing said derivatives, and the uses thereof

The invention relates to a novel acetylcholinesterase gene (ace-1) responsible for resistance to organophosphorus and/or carbamates in mosquitoes, which is non-homologous to theacetylcholinesterase gene (ace-2), products of the ace-1 gene (cDNA, protein AchE1) and the applications thereof, particularly for the screening of novel insecticides and the genetic detection of resistance to organophosphorus and/or carbamates in mosquito populations.

Acetylcholinesterase gene responsible for insecticide resistance and applications thereof

Growing community of inventors

Castelnau le Lez, France

Philippe Fort